NeurogesX Raises $20 Million in Private Equity Financing; Proceeds to Fund U.S. Pivotal Clinical Trials and Planned European Filing

NeurogesX Raises $20 Million in Private Equity Financing; Proceeds to Fund U.S. Pivotal Clinical Trials and Planned European Filing

Business Wire - December 1, 2005

SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of novel treatments for relief of neuropathic pain, today announced that it has completed a $20 million private equity financing. The company believes that proceeds from this financing will be sufficient to complete its current U.S. pivotal clinical program and to support its European marketing application for Transacin(TM), NeurogesX's proprietary dermal patch for the treatment of neuropathic pain. NeurogesX plans to submit a marketing application for Transacin in the European Union in the second half of 2006, and expects to file new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for PHN and HIV-AN in mid-2007.

Participants in this financing included international investors MC Life Science Ventures, a subsidiary of Mitsubishi Corporation and Mitsubishi International Corporation, MunMun International LTD, and Saudi Venture Development Company, as well as NeurogesX's existing investors ARCH Venture Partners, Alta Partners, Montreux Equity Partners, Global LifeScience Ventures, and Walden International Venture Partners. With the completion of this financing, the company has raised a total of approximately $85 million since its first equity financing in June 2000.

"This financing enables us to complete our clinical development programs for Transacin in both postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN)," said Anthony DiTonno, NeurogesX president and CEO. "We are also excited about strengthening our international investor base and expect to leverage these relationships in furthering our worldwide partnering efforts as Transacin nears commercial launch."

"We are very impressed with NeurogesX's clinical development successes with Transacin to date," said Claudio Lipcic, associate, Mitsubishi International Corporation. "Pain is a notoriously difficult area with which to achieve clinical success. NeurogesX has developed a compelling clinical program that we believe will lead to the introduction of a novel product to address large unmet medical needs in the neuropathic pain market."

About Transacin

Transacin is a neuropathic pain treatment that is clinically administered via a dermal patch. Transacin has a profile unlike currently available neuropathic pain treatment options, which are associated with systemic side effects and inconvenient dosing regimens. The company has studied the effects of Transacin in more than 500 patients suffering from PHN and approximately 100 with painful diabetic neuropathy (PDN) with no reported significant safety issues to date.

NeurogesX is currently conducting a pivotal trial with Transacin for the treatment of PHN and plans to initiate a second pivotal trial in PHN in early 2006. In HIV-AN, NeurogesX announced in May 2005 results of a Phase 3 clinical trial in which it had achieved statistical significance in the primary endpoint of pain reduction compared to baseline. The company plans to initiate a confirmatory Phase 3 trial in HIV-AN in early 2006. Transacin has been granted orphan drug and fast track status for HIV-AN by the FDA.

About NeurogesX

NeurogesX is a privately held specialty pharmaceutical company focused on the development of novel treatments for the management of neuropathic pain and improving quality of life using advanced neuroscience insights and innovative delivery technologies. The company's initial products are focused on the treatment of chronic pain in the areas of postherpetic neuralgia (PHN), painful HIV-associated sensory neuropathy (HIV-AN) and painful diabetic neuropathy (PDN). Additional information about NeurogesX can be found at www.neurogesx.com.

NeurogesX is a trademark of NeurogesX, Inc. All other trademarks and registered trademarks are those of their respective companies.

CONTACT: NeurogesX, Inc.

Anthony A. DiTonno, 650-508-2116

aditonno@neurogesx.com

Stephen F Ghiglieri, 650-508-2116

sghiglieri@neurogesx.com

Lippert/Heilshorn & Associates

Jody Cain, 310-691-7100

jcain@lhai.com

Brandi Floberg, 310-691-7100

bfloberg@lhai.com

SOURCE: NeurogesX, Inc.
051201
BW051203

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .